WenhuaYu Ph.D. (Jocelyn)

Associate

San Diego + 1.858.314.1186

Connect:

Share

Dr. Jocelyn Yu's practice focuses on counseling clients on strategies for maximizing intellectual property (IP) protection and leveraging IP rights in business strategies and transactions. She services a wide spectrum of clients in the life science industry, ranging from biotech start-ups to the world's largest pharmaceutical companies.

Jocelyn has extensive experience in preparing and prosecuting patent applications in various countries and in jurisdictions around the world, as well as constructing and managing global patent portfolios. Her main technology areas include genetic engineering, microbiology, immunotherapies (e.g., antibodies, CAR-T, CpG), diagnostics and precision medicine, gene editing, and natural peptide platform technology. She also frequently conducts due diligence investigations to assist with client's IP and business strategies, including patent evaluations, IP landscape searches, patentability opinions, validity opinions, and freedom-to-operate opinions.

On the transactional side of her practice, Jocelyn counsels clients on legal and business issues relating to technology, IP, and commercial transactions. She also assists biotech and pharmaceutical companies constructing their technology transactions and collaborations (e.g., joint research and development collaborations, funded researches, and IP licensing transactions), including U.S.-China cross-border transactions. She assists with negotiations, reviews and prepares various types of commercial agreements involving IP rights, and conducts due diligence investigations in support of the transaction.

Prior to joining Jones Day, Jocelyn worked in patent law at two international law firms. While earning her Ph.D. at Pennsylvania State University, Jocelyn worked in the areas of genetic and molecular mechanisms of synaptic neurotransmission and coauthored several peer-reviewed scientific publications.

Experience

  • AbbVie acquires Mitokinin, Inc.Jones Day advised AbbVie Inc. in its exclusive right to acquire Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
  • Burning Rock establishes global patent portfolio for NGS-related diagnostics and precision oncologyJones Day represents Burning Rock in the development and prosecution of global patent portfolios related to next generation sequencing (NGS) technology for diagnostic and of precision oncology.
  • Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirusJones Day represented Shanghai Junshi Biosciences Co., Ltd. in its strategic collaboration and license agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of two antibodies for the prevention and treatment of the COVID-19 SARS-CoV-2 novel coronavirus.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • VersaPeutics collaborates with UCSD in developing pharmaceutical candidates for treatment of neurological and oncological diseasesJones Day represented VersaPeutics, Inc. in its strategic collaboration and license agreement with University of California San Diego ("UCSD") for the development of pre-clinical stage therapeutic candidates for the treatment of certain neurological and oncological diseases.
  • Sanofi and Denali Therapeutics collaborate to develop treatments for neurological and inflammatory diseasesJones Day represented Sanofi in its strategic collaboration and license agreement with Denali Therapeutics for the development, manufacturing, and commercialization of many pre-clinical and clinical candidates for treatment of certain neurological and systemic inflammatory diseases, including those known to target RIPK1, such as MS, Alzheimer's Disease and ALS, and rheumatoid arthritis.
  • Celgene acquires Juno Therapeutics for $9 billionOn behalf of Celgene Corporation, Jones Day conducted a large-scale intellectual property due diligence review and evaluation of matters related to its definitive merger agreement and acquisition of Juno Therapeutics for approximately $9 billion, including Juno’s technology related to CAR-T and TCR cellular immunotherapeutics for use in oncology and other indications.
  • Celgene develops global patent portfolio for agonistic anti-PD1 antibody therapeuticsJones Day represents Celgene Corporation in the establishment of a global patent portfolio related to agonistic anti-PD1 therapeutic antibodies.
    • View All

    November 2018 Blog

    Assignor Estoppel Does Not Apply to IPRs, PTAB Litigation Blog

    Speaking Engagements

    • November 7, 2018
      Licensing Fundamentals for Business Executives and Startups

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.